- Home
- EWTX vs NVCR Comparison
EWTX vs NVCR Comparison
Compare EWTX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- NVCR
- Stock Information
- Founded
- EWTX 2017
- NVCR 2000
- Country
- EWTX United States
- NVCR Switzerland
- Employees
- EWTX N/A
- NVCR N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- EWTX Health Care
- NVCR Health Care
- Exchange
- EWTX Nasdaq
- NVCR Nasdaq
- Market Cap
- EWTX 1.5B
- NVCR 1.4B
- IPO Year
- EWTX 2021
- NVCR 2015
- Fundamental
- Price
- EWTX $13.93
- NVCR $11.54
- Analyst Decision
- EWTX Buy
- NVCR Buy
- Analyst Count
- EWTX 8
- NVCR 7
- Target Price
- EWTX $41.13
- NVCR $28.79
- AVG Volume (30 Days)
- EWTX 633.0K
- NVCR 2.2M
- Earning Date
- EWTX 08-07-2025
- NVCR 07-24-2025
- Dividend Yield
- EWTX N/A
- NVCR N/A
- EPS Growth
- EWTX N/A
- NVCR N/A
- EPS
- EWTX N/A
- NVCR N/A
- Revenue
- EWTX N/A
- NVCR $630,160,000.00
- Revenue This Year
- EWTX N/A
- NVCR $6.15
- Revenue Next Year
- EWTX N/A
- NVCR $7.35
- P/E Ratio
- EWTX N/A
- NVCR N/A
- Revenue Growth
- EWTX N/A
- NVCR 14.58
- 52 Week Low
- EWTX $10.60
- NVCR $10.87
- 52 Week High
- EWTX $38.12
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- EWTX 52.63
- NVCR 32.75
- Support Level
- EWTX $12.30
- NVCR $10.87
- Resistance Level
- EWTX $14.11
- NVCR $11.99
- Average True Range (ATR)
- EWTX 0.73
- NVCR 0.57
- MACD
- EWTX 0.00
- NVCR 0.10
- Stochastic Oscillator
- EWTX 53.80
- NVCR 25.17
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.